 Connection
Jordana Hoppe to Quinolines
This is a "connection" page, showing publications Jordana Hoppe has written about Quinolines.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.298 |
|
|
|
-
Metcalf A, Martiniano SL, Sagel SD, Zaretsky MV, Zemanick ET, Hoppe JE. Outcomes of prenatal use of elexacaftor/tezacaftor/ivacaftor in carrier mothers to treat meconium ileus in fetuses with cystic fibrosis. J Cyst Fibros. 2025 May; 24(3):466-468.
Score: 0.196
-
Muther EF, Gibson SL, Ford C, Duncan C, Riekert KA, Lyons E, Hoppe JE, Prickett M, Isenburg MV, Everhart RS. People with cystic fibrosis' experience of symptom burden while taking elexacaftor/tezacaftor/ivacaftor. Respir Med. 2026 Aug; 259:108908.
Score: 0.054
-
Mayer-Hamblett N, Gifford AH, Kloster M, Russell R, Braun AT, Gibson RL, Hoppe JE, Jain R, Linnemann RW, Liou TG, Lysinger J, Milla C, Riekert KA, Sawicki GS, Young J, Nichols D. Impact of Discontinuing Both Hypertonic Saline and Dornase Alfa after Elexacaftor-Tezacaftor-Ivacaftor in Cystic Fibrosis. Ann Am Thorac Soc. 2024 11; 21(11):1507-1515.
Score: 0.049
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|